Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 424-430

  Ming, Xin ^a   Ju, Wujian ^a   Wu, Huali ^b   Tidwell, Richard R ^b   Hall, James E ^a,b   Thakker, Dhiren R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DIAMIDINE DERIVATIVE; FURAMIDINE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PENTAMIDINE; RANITIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BILE; CHO CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; IC 50; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANTIFUNGAL AGENTS; BENZAMIDINES; BIOLOGICAL TRANSPORT; CATIONS; FEMALE; GLUCURONIDES; HUMANS; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; PENTAMIDINE;

CRICETULUS GRISEUS; MAMMALIA; PROTOZOA;

EID: 59649084045     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024083     Document Type: Article

References (36)

1. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
2. Barrett MP, Boykin DW, Brun R, and Tidwell RR (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152:1155-1171.
3. Bednarczyk D, Ekins S, Wikel JH, and Wright SH (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63:489-498.
4. Benet LZ and Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121.
5. Bourdet DL, Pritchard JB, and Thakker DR (2005) Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315:1288-1297.
6. Bronner U, Ericsson O, Nordin J, Wikström I, Abdi YA, Hall JE, Tidwell RR, and Gustafsson LL (1995) Metabolism is an important route of pentamidine elimination in the rat: disposition of 14C-pentamidine and identification of metabolites in urine using liquid chromatography-tandem mass spectrometry. Pharmacol Toxicol 77:114-120.
7. Carter NS, Berger BJ, and Fairlamb AH (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 270:28153-28157.
8. Chen Y, Zhang S, Sorani M, and Giacomini KM (2007) Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 322:695-700.
9. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, and Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167:1477-1484.
10. Conte JE Jr (1991) Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 163:169-175.
11. Das BP and Boykin DW (1977) Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem 20:531-536.
12. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881.
13. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, and Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552.
14. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
15. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, and Taubert D (2008) Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36:1616-1623.
16. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
17. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251.
18. Lansiaux A, Dassonneville L, Facompré M, Kumar A, Stephens CE, Bajic M, Tanious F, Wilson WD, Boykin DW, and Bailly C (2002) Distribution of furamidine analogues in tumor cells: influence of the number of positive charges. J Med Chem 45:1994-2002.
19. Li M, Anderson GD, and Wang J (2006) Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2:505-532.
20. Meijer DK, Smit JW, Hooiveld GJ, van Montfoort JE, Jansen PL, and Müller M (1999) The molecular basis for hepatobiliary transport of organic cations and organic anions. Pharm Biotechnol 12:89-157.
21. Midgley I, Fitzpatrick K, Taylor LM, Houchen TL, Henderson SJ, Wright SJ, Cybulski ZR, John BA, McBurney A, Boykin DW, et al. (2007) Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/ antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydro- chloride). Drug Metab Dispos 35:955-967.
22. O'Brien JG, Dong BJ, Coleman RL, Gee L, and Balano KB (1997) A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 24:854-859.
23. Pentikäinen PJ, Neuvonen PJ, and Penttilä A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 16:195-202.
24. Saulter JY (2005) Permeability and metabolism of potential prodrugs for the antimicrobial agent 2,5 bis(4-amidinophenyl)furan (DB75), in School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC.
25. Schoonen WG, de Roos JA, Westerink WM, and Debiton E (2005) Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 19:491-503.
26. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, et al. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280.
27. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, and Sugiyama Y (2005) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337-345.
28. Thomas SH, Page CJ, Blower PJ, Chowienczyk P, Ward A, Kamali F, Bradbeer CS, Bateman NT, and O'Doherty MJ (1997) Disposition of intravenous 123iodopentamidine in man. Nucl Med Biol 24:327-332.
29. Urakami Y, Akazawa M, Saito H, Okuda M, and Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13: 1703-1710.
30. Urban TJ and Giacomini KM (2007) Organic cation transporters, in Drug Transporters: Molecular Characterization and Role in Drug Disposition (You G and Morris ME eds) pp 11-34, Wiley-Interscience, Hoboken, NJ.
31. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, and Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515.
32. Weiner IM and Roth L (1981) Renal excretion of cimetidine. J Pharmacol Exp Ther 216:516-520.
33. Wright SH (2005) Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol 204:309-319.
34. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, and Inui K (2007) Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 74:477-487.
35. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, and Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51:913-921.
36. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847-8857.